Get the Stockscreener App
13.17
0.77%
0.10
After Hours:
13.60
0.43
+3.26%
Crescent Biopharma Inc stock is traded at $13.17, with a volume of 134.26K.
It is up +0.77% in the last 24 hours and up +0.30% over the past month.
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.
See More
Previous Close:
$13.07
Open:
$13.09
24h Volume:
134.26K
Relative Volume:
0.96
Market Cap:
$221.03M
Revenue:
$6.67M
Net Income/Loss:
$-47.55M
P/E Ratio:
-8.78
EPS:
-1.5
Net Cash Flow:
$-17.44M
1W Performance:
-7.71%
1M Performance:
+0.30%
6M Performance:
+2,476%
1Y Performance:
+2,476%
1-Day Range:
$12.86
$13.31
1-Week Range:
$12.27
$16.35
52-Week Range:
$9.81
$21.40
Crescent Biopharma Inc Stock (CBIO) Company Profile
Name
Crescent Biopharma Inc
Sector
Industry
Phone
617-430-5595
Address
300 FIFTH AVENUE, WALTHAM, CA
Compare CBIO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CBIO
Crescent Biopharma Inc
|
13.17 | 219.35M | 6.67M | -47.55M | -17.44M | -1.50 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.04 | 115.56B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
703.26 | 75.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
430.02 | 60.52B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
900.76 | 55.48B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
196.55 | 43.51B | 447.02M | -1.18B | -906.14M | -6.1812 |
Crescent Biopharma Inc Stock (CBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-25-25 | Initiated | Jefferies | Buy |
| Aug-11-25 | Initiated | H.C. Wainwright | Buy |
| Jul-14-25 | Initiated | Wedbush | Outperform |
| Jun-25-25 | Initiated | Stifel | Buy |
| Mar-21-25 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-11-25 | Initiated | Noble Capital Markets | Outperform |
| Jul-26-24 | Downgrade | TD Cowen | Buy → Hold |
| Dec-22-23 | Initiated | CapitalOne | Overweight |
| Nov-12-21 | Upgrade | Jefferies | Hold → Buy |
| Apr-29-21 | Resumed | Stephens | Overweight |
| Feb-10-21 | Initiated | Piper Sandler | Overweight |
| May-21-20 | Initiated | Raymond James | Outperform |
| Nov-14-19 | Initiated | ROTH Capital | Buy |
| Aug-05-19 | Downgrade | Jefferies | Buy → Hold |
| Aug-05-19 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Aug-05-19 | Downgrade | SunTrust | Buy → Hold |
| Apr-12-19 | Initiated | Piper Jaffray | Overweight |
| Jan-04-19 | Initiated | Oppenheimer | Outperform |
| Dec-18-18 | Initiated | H.C. Wainwright | Buy |
| Feb-12-18 | Reiterated | B. Riley FBR, Inc. | Buy |
| Feb-09-18 | Reiterated | Chardan Capital Markets | Buy |
| Dec-08-17 | Initiated | B. Riley FBR, Inc. | Buy |
| Jun-12-17 | Initiated | Chardan Capital Markets | Buy |
| Jun-06-17 | Initiated | Ladenburg Thalmann | Buy |
| Jul-26-16 | Initiated | SunTrust | Buy |
| Jun-30-16 | Initiated | Rodman & Renshaw | Buy |
| Mar-17-15 | Reiterated | Stifel | Buy |
View All
Crescent Biopharma Inc Stock (CBIO) Latest News
Fairmount Funds Management Llc Purchases 1,360,000 Shares of Crescent Biopharma (NASDAQ:CBIO) Stock - MarketBeat
Affinity Asset Advisors LLC Makes New $4.52 Million Investment in Crescent Biopharma, Inc. $CBIO - MarketBeat
China's Kelun-Biotech licenses cancer treatment to Crescent Biopharma - Reuters
Crescent Biopharma (NASDAQ:CBIO) Lowered to "Sell" Rating by Wall Street Zen - MarketBeat
Crescent Biopharma (NASDAQ:CBIO) Lowered to “Sell” Rating by Wall Street Zen - Defense World
Crescent, Kelun in two-way deal, including PD-1/VEGF bispecific - BioWorld MedTech
Crescent Biopharma partners with Kelun-Biotech in oncology - BioWorld MedTech
Crescent and Kelun-Biotech swap cancer asset rights in double deal - Yahoo Finance
Check Out Crescent Biopharma Inc (CBIO)’s Trade Data Rather Than the Analysts’ Views - Setenews
Asia Deal Watch: Kelun And Crescent Partner And Cross-License Cancer Candidates - Citeline News & Insights
China’s Kelun-Biotech licenses cancer treatment to Crescent Biopharma - 1470 & 100.3 WMBD
Crescent Biopharma stock price target raised by Stifel to $32 on Kelun deal - Investing.com South Africa
Sichuan Kelun-Biotech biopharmaceutical partners with Crescent Biopharma - marketscreener.com
What's Happening With Crescent Biopharma Stock Today? - Benzinga
Crescent and Kelun-Biotech get creative with two-way licensing deal - The Pharma Letter
The Deal That Sent Crescent Biopharma Shares Surging Over 40% Pre-Market Today - Asianet Newsable
Kelun-Biotech And Crescent Biopharma Announce Strategic Partnership - TradingView
Crescent Biopharma partners with Kelun-Biotech, raises $185 million By Investing.com - Investing.com Nigeria
Crescent Biopharma stock soars after Kelun-Biotech partnership By Investing.com - Investing.com South Africa
Crescent, Kelun-Biotech Sign Oncology Deal; Crescent To Raise $185 Mln; Stock Up - Nasdaq
Crescent Biopharma partners with Kelun-Biotech, raises $185 million - Investing.com India
Kelun-Biotech and Crescent Biopharma… - digitalmore.co
Crescent Biopharma jumps after cancer drug partnership - TradingView
Crescent Biopharma, Kelun-Biotech Biopharmaceutical Partner in Multimillion Dollar Deal to Develop Cancer Drugs - MarketScreener
Kelun-Biotech and Crescent Biopharma form oncology partnership - Investing.com
Kelun-Biotech and Crescent Biopharma Announce Strategic Partnership to Develop and Commercialize Novel Oncology Therapeutics - PR Newswire
Kelun-Biotech and Crescent Biopharma form oncology partnership By Investing.com - Investing.com UK
Is Crescent Biopharma Inc. (GKO0) stock a top hedge fund pickForecast Cut & Low Drawdown Momentum Trade Ideas - Newser
Crescent Biopharma Announces Transformational Partnership with Kelun-Biotech and $185 Million Private Placement, Accelerating and Expanding Global Pipeline of Next Generation Therapeutics for Solid Tumors - GlobeNewswire
Crescent Biopharma (Nasdaq: CBIO) and Kelun-Biotech to move CR-001, SKB105 into Phase 1/2 trials in 2026 - Stock Titan
Jefferies Financial Group Inc. Buys New Stake in Crescent Biopharma, Inc. $CBIO - MarketBeat
Crescent Biopharma (NASDAQ:CBIO) Share Price Crosses Above 200-Day Moving AverageHere's Why - MarketBeat
Crescent Biopharma Inc (CBIO) - MSN
Crescent Biopharma (NASDAQ:CBIO) Share Price Crosses Above 200-Day Moving Average – Here’s Why - Defense World
Crescent Biopharma Advances Cancer Therapy Pipeline - MSN
MSN Money - MSN
Is Crescent Biopharma Inc. (GKO0) stock protected from inflationJuly 2025 Institutional & Weekly Top Performers Watchlists - newser.com
Will Crescent Biopharma Inc. (GKO0) stock recover faster than industryJuly 2025 Opening Moves & Safe Entry Point Alerts - newser.com
What valuation ratios show for Crescent Biopharma Inc. (GKO0) stock2025 Top Decliners & Daily Entry Point Alerts - newser.com
Crescent Biopharma, Inc. (NASDAQ:CBIO) Receives Average Recommendation of “Buy” from Analysts - Defense World
Crescent Biopharma, Inc. (NASDAQ:CBIO) Receives Average Recommendation of "Buy" from Analysts - MarketBeat
Crescent Biopharma (Nasdaq: CBIO) Approves 451,448-Share Inducement Options at $13.02 - Stock Titan
Crescent Biopharma Inc Stock (CBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.67%
0.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):